top of page

The Science behind the technology of Cell4Cure

Dendritic cells (DCs) are mediators between innate and adaptive immunity and can initiate or moderate antigen-specific immune responses based on their phenotypic profile i.e., whether they are activating or tolerogenic. They exert their effects by presenting antigens on their surfaces to other cells of the immune system. The fact that DCs with a tolerogenic phenotype can be generated in vitro, offers the opportunity to feed those cells with specific antigens known to be involved in various immunological disease processes. Adoptive transfer of antigen-fed tolerogenic DCs can then specifically prevent or interfere with diseases caused by such undesirable immune activation. By antigen-specific intervention rather than by general immunosuppression, the immune system maintains its capability to respond to infections and cancer.

sid 6 transp.png

Cell4Cure has developed a method by which DCs with a tolerogenic phenotype can be efficiently generated in vitro using a propriety cocktail of reagents added to the cells in a defined order. Tolerogenic DCs are anticipated to interfere with both humoral and cellular immune responses by induction of regulatory T- and B-cells as well as via direct effects exerted by the DCs themselves. Because the tolerogenic DCs can be fed different antigens depending on the disease to be treated, the potential uses of this platform technology is vast, including inhibiting antibody responses to biological drugs, autoimmune diseases and transplant rejection.

sid 9.png



Tolerogenic dendritic cells generated in vitro using a novel protocol mimicking mucosal tolerance mechanisms represent a potential therapeutic cell platform

for induction of immune tolerance​

Gillian Dao Nyesiga, Lieneke Pool, Pavlos C. Englezou, Terese Hylander, Lars Ohlsson,

Daniel Appelgren, Anette Sundstedt, Kristina Tillerkvist, Hanne R. Romedahl and Maria Wigren​

Front. Immunol. 2023 Oct 13:14:1045183. doi: 10.3389/fimmu.2023.1045183

Autologous cell therapy – A new concept to eradicate inhibitors in haemophilia​

Hanjing Xie, Rolf Ljung, Jan Astermark and Terese Hylander​

Hemophilia 2022 Nov;28(6):e259-e261. doi: 10.1111/hae.14663. Epub 2022 Sep 19

bottom of page